

# ChemComm

Chemical Communications

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: M. Greaney, S. Johnson and E. Kovács, *Chem. Commun.*, 2020, DOI: 10.1039/D0CC00220H.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

## COMMUNICATION

## Arylation and Alkenylation of Activated Alkyl Halides using Sulfonamides

Received 00th January 20xx,  
Accepted 00th January 20xxStuart Johnson, Ervin Kovács and Michael F. Greaney,\*<sup>a</sup>

DOI: 10.1039/x0xx00000x



A variety of quaternary aryl amino acid derivatives can be synthesised using tandem  $S_N2$  / Smiles rearrangement chemistry involving aryl sulfonamides and  $\alpha$ -chloro carbonyl compounds. The reaction harnesses a sulfur dioxide extrusion pathway to construct a C-N and C-C<sub>aryl</sub> bond under simple conditions with no requirement for organometallics or transition metal catalysts. The reaction is also successful for alkenyl sulfonamides, producing sterically congested quaternary alkene amino acid derivatives.

Tandem reactions of sulfonamides create powerful arylation pathways to nitrogenous aromatic structures of the type commonly found in pharmaceuticals. The concept is set out in Scheme 1, and involves reacting sulfonamide **1**, frequently commercially available or easily prepared, with a suitable electrophile to create a C-N bond. The intermediate anionic structure **3** can then undergo a Smiles aryl transfer reaction,<sup>1</sup> creating a C-C<sub>aryl</sub> bond with extrusion of  $SO_2$ .<sup>2</sup> Overall, the process accesses valuable arenes under simple reaction conditions, with no recourse to the precious metal catalysis that is frequently required for arylation and C-N bond forming chemistry. The intramolecular  $S_NAr$  step does generally require an electron-poor or heteroaromatic moiety for successful reaction, but this restriction is mitigated by these functional groups being commonly represented in biologically active molecules.


We have previously explored  $sp$  and  $sp^2$  electrophiles in this tandem Smiles process, and were interested in expanding this idea to  $sp^3$  centres to create new routes to amino-arylated products.<sup>3</sup> Alkyl halides are readily available and versatile electrophiles that could react *via*  $S_N$  chemistry, setting up a rearrangement as shown in Scheme 1B, creating a particularly valuable quaternary arylated amine motif **8**. The proposed Smiles reaction formally requires a strained four-membered Meisenheimer intermediate **10**, distinct from our earlier work with  $\pi$ -electrophiles that create pentacyclic re-arrangements

for aryl transfer. There is good precedent in the literature, however, for this step with a number of nosylated amino acid derivatives being observed to rearrange on treatment with base.<sup>4</sup> Successful reaction would produce quaternary  $\alpha$ -aryl amino acid derivatives, common motifs in drugs, agrochemicals and peptidomimetics (Scheme 1C).<sup>5</sup>

## A: Tandem Sulfonamide Arylations

B: This Work:  $sp^3$  Aminoarylation

## C: Quaternary aryl amino acid derivatives




Scheme 1: Proposed tandem Smiles aminoarylation

We began by screening reaction conditions for the tandem  $S_N2$  / Smiles arylation of ethyl  $\alpha$ -chlorophenylacetate **7a** with *N*-methylnosylamide **6a**. We were pleased to observe that simple  $K_2CO_3$  treatment in hot DMF led to successful conversions, with optimal conditions being a 2:1 ratio of alkyl halide to sulfonamide, 3 equiv of base and heating to 70 °C, forming **8a** in high yield (Scheme 2). Some simple mapping of functional group scope established that the reaction favoured *N*-substitution on the sulfonamide; primary sulfonamides gave **8b** in very low yield and *N,N*-disubstituted sulfonamides were unreactive. A ketone in place of the ester group led to

<sup>a</sup> School of Chemistry, University of Manchester, Oxford Rd, Manchester M13 9PL, UK

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

substantially diminished yields (**8c**), so we retained the ester group for scope studies. A range of aryl-substituted *N*-methylsulfonamides were productive (**8a** – **8f**), along with several weakly nucleophilic *N*-arylsulfonamides (products **8g** – **8l**). Electron donating arene substituents were noticeably more effective than electron withdrawing ones (e.g. **8h** and **8j** v **8i**), but steric hindrance on the sulfonamide (e.g. *N*-mesityl **8i**) lowered yields considerably. Changing the phenyl group in the alkyl halide substrate was feasible, with methyl groups being tolerated (**8n** and **8o**) and the malonate substrate successfully affording the versatile diester product **8p**. Finally, the heterocyclic pyrimidine sulfonamide was productive to yield the novel amino acid derivative **8q** in 54% yield.





**Scheme 2:** Scope of tandem S<sub>N</sub>2/Smiles rearrangement. <sup>a</sup> Reaction carried out at room temp.


Reaction of the unsubstituted ethyl chloroacetate **7c** with *N*-aryl substituted sulfonamides unexpectedly gave rise to imine products (Scheme 3). It appears that the initial secondary aryl Smiles product is undergoing oxidation under the basic conditions with adventitious air in the reaction.<sup>6</sup> The transformation was general for *N*-arylsulfonamides, affording the Schiff base aryl glyoxalate derivatives **11a** – **f**. The aryl glycine derivative **12a** could be accessed through a Ni-catalyzed borohydride reduction of the imine **11a**.

Having established an effective aminoarylation protocol, we wondered if we could achieve an aminoalkenylation using similar sulfonamide S<sub>N</sub>2 / Smiles rearrangement chemistry (Scheme 4). Alkenyl transfer through desulfonylative processes

is precedented in the radical regime,<sup>7</sup> but anionic reactions are rare.<sup>8</sup> A successful metal-free synthesis of quaternary alkenyl amino acid derivatives would complement existing routes, which typically involve addition of sp organometallics to the appropriate imine and subsequent hydrogenation to the alkene.<sup>9</sup> In the event, we were pleased to observe the known alkenyl sulfonamide **13a**<sup>10</sup> undergoing successful tandem S<sub>N</sub> / alkenyl transfer reaction under the standard conditions, to give **14a**, albeit in a low 35% yield. The *N*-methyl sulfonamide **13b** was more efficient, producing the alkene **14b** in 59% yield.



**Scheme 3:** Substituted imine scope using ethyl chloroacetate



**Scheme 4:** Vinylogous Smiles rearrangement for alkenylation

In conclusion, we have developed a new tandem process for the rapid construction of quaternary amino acid derivatives. The protocol takes commercially available sulfonamides and alkyl halides, and effects C–N and C–C<sub>aryl</sub> bond formation under simple, metal-free conditions. The reaction could be extended to imine synthesis, using ethyl chloroacetate, and a novel vinylogous Smiles process to access alkenylated quaternary amino acids.

## Conflicts of interest

There are no conflicts to declare.

View Article Online  
DOI: 10.1039/D0CC00220H

## Notes and references

1. C. M. Holden and M. F. Greaney, *Chem. Eur. J.* 2017, **23**, 8992. b) A. R. P. Henderson, J. R. Kosowan and T. E. Wood, *Can. J. Chem.* 2017, **95**, 483.
2. Recent examples: a) X. Gao, C. Li, Y. Yuan, X. Xie, and Z. Zhang, *Org. Biomol. Chem.* 2020, **18**, 263. b) J. Liu, D. Ba, W. Lv, Y. Chen, Z. Zhao, and G. Cheng, *Adv. Synth. Catal.* 2020, in press, DOI: 10.1002/adsc.201900960. c) V. G. Haensch, T. Neuwirth, J. Steinmetzer, F. Kloss, R. Beckert, S. Gräfe, S. Kupfer, and C. Hertweck, *Chem. Eur. J.* 2019, **25**, 16068. d) D. M. Whalley, H. A. Duong, M. F. Greaney, *Chem. Eur. J.* 2019, **25**, 1927; b) S. O. Rashid, S. S. Almadhhi, D. J. Berrisford, J. Raftery, I. Vitorica-Yrezabal, G. Whitehead, P. Quayle, *Tetrahedron*, 2019, **75**, 2413; c) R. Bujok, M. Makosza, *M. Synthesis*, 2019, **51**, 3109; d) T. M. Monos, R. C. McAtee, C. R. J. Stephenson, *Science*, 2018, **361**, 1369; e) S. Coulibali, T. Godou, S. Canesi, *Org. Lett.* 2016, **18**, 4348; f) S. W. Crossley, R. M. Martinez, S. Guevara-Zuluaga, R. A. Shenvi, *Org. Lett.* 2016, **18**, 2620; g) J. J. Douglas, H. Albright, M. J. Sevrin, K. P. Cole, C. R. J. Stephenson, *Angew. Chem. Int. Ed.* 2015, **54**, 14898; h) N. Fuentes, W. Kong, L. Fernandez-Sanchez, E. Merino, C. Nevado, *J. Am. Chem. Soc.* 2015, **137**, 964; i) W. Kong, N. Fuentes, A. Garcia-Dominguez, E. Merino, C. Nevado, *Angew. Chem. Int. Ed.* 2015, **54**, 2487.
3. a) C. M. Holden, S. M. A. Sohel and M. F. Greaney, *Angew. Chem. Int. Ed.* 2016, **55**, 2450. b) P. G. T. Rabet, S. Boyd, and M. F. Greaney, *Angew. Chem. Int. Ed.* 2017, **56**, 4183. c) H. L. Barlow, P. G. T. Rabet, A. Durie, T. Evans, and M. F. Greaney, *Org. Lett.* 2019, **21**, 9033.
4. a) E. Negishi and A. R. Day, *J. Org. Chem.* 1965, **30**, 43. b) M. W. Wilson, S. E. Ault-Justus, J. C. Hodges, J. R. Rubin, *Tetrahedron*, 1999, **55**, 1647. c) V. Lupi, M. Penso, F. Foschi, F. Gassa, V. Mihali, and A. Tagliabue, *Chem. Commun.* 2009, 5012. d) F. Foschi, D. Landini, V. Lupi, V. Mihali, M. Penso, T. Pilati, and A. Tagliabue, *Chem. Eur. J.* 2010, **16**, 10667. e) P. Smyslova, K. Kisseljova, and V. Krchňák, *ACS Comb. Sci.* 2014, **16**, 500. f) V. Gimenez-Navarro, T. Volna, and V. Krchňák, *ACS Comb. Sci.* 2015, **17**, 433. g) M. Bezanson, A. Tomberg, and N. Moitessier, *J. Org. Chem.* 2017, **82**, 2579. h) C. R. Goncalves, M. Lemmerer, C. J. Teskey, P. Adler, D. Kaiser, B. Maryasin, L. Gonzalez, and N. Maulide, *J. Am. Chem. Soc.* 2019, **141**, 18437.
5. D. L. Leonard, J. W. Ward, and J. Clayden, *Nature*, 2018, **562**, 105.
6. J. Hao, Y. Xu, Z. Xu, Z. Zhang, and W. Yang, *Org. Lett.* 2018, **20**, 7888.
7. a) J. J. Kohler and W. N. Speckamp, *Tetrahedron Lett.*, 1977, **18**, 635. b) C. R. A. Godfrey, P. Hegarty, W. B. Motherwell, and M. K. Uddin, *Tetrahedron Lett.* 1998, **39**, 723. c) X. Wang, J. Liu, Z. Yu, M. Guo, X. Tang, and G. Wang, *Org. Lett.* 2018, **20**, 6516.
8. E. Waldau and R. Pütter, *Angew. Chem. Int. Ed.*, **1972**, **11**, 826.
9. P. Wipf and C. R. J. Stephenson, *Org. Lett.* 2003, **5**, 2449.
10. F. G. Bordwell, A. B. Colbert, and B. Alan, *J. Am. Chem. Soc.* 1946, **68**, 1778.